Studies have shown that simultaneous blockade of both activin A and MSTN, both ligands of ActRIIA/B, produces greater increases in muscle mass than inhibiting either alone.[82] This finding is supported by clinical trials, where combined treatment with trevogrumab (anti-MSTN) and garetosmab (anti-activin A) increased total body muscle volume and reduced fat mass compared with placebo or either antibody alone.[83] Overall, activin A inhibitors are as promising as MSTN inhibitors, and their combination may yield superior outcomes
Wang H, Wang L, Li Y, Luo S, Ye J, Lu Z, et al
But what happens if youre on them when you get pregnant especially before you even realise youre pregnant
The reviewed trials indicate cardiorenal benefits of SGLT2i in patients regardless of diabetes status
Find articles by Momen, A
Wall Street analysts expect between $33 billion and $100 billion in annual revenue from anti-obesity medications in the next six years, according to J.P